Webinar

EFFECTIVENESS AND LIMITATIONS OF COMPULSORY LICENSES TO PROMOTE ACCESS TO MEDICINES

EDUARDO URIAS, DANIELLE NAVARRO

29 June 2021

Q&A Session with the Participants

16:09:19
From Global Health Centre Research, Graduate Institute Geneva to Everyone: Welcome to the Knowledge Network Webinar Series at the Global Health Centre, The Graduate Institute of Geneva. Thank you for joining us. The recording and materials from the webinar will be made available at: https://www.knowledgeportalia.org/webinars. If you have any questions or comments, please type them in the chat box (don't forget to select "panelists and attendees"). You can also raise hand to pose your questions verbally. You can subscribe to our mailing list: graduateinstitute.ch/globalhealth

16:10:52
From Aymeric Conry to Panelists: Thank you very much for this fascinating event! Could we then have an access to the presentation, to use the content in our researches and work?

16:11:27
From Global Health Centre Research, Graduate Institute Geneva to Everyone:
The research paper being presented by Dr Eduardo Urias is available at:
https://link.springer.com/article/10.1057/s42214-020-00068-4

16:22:24
From Enrica Alteri to Everyone: How does the price reduction due to CL compare to price reduction when a drug becomes generic (off-patent)

16:23:09
From Lynette Mabote to Panelists: Kindly share the presentations

16:23:53
From Anima Sharma to Everyone: Session is wonderful. However, I have some imp work hence have to leave. Will see the recording.

16:24:01
From Global Health Centre Research, Graduate Institute Geneva to Everyone: The recording and materials from the webinar will be made available at: https://www.knowledgeportalia.org/webinars.

16:28:59
From Susan Adong to Everyone: Uganda's quality chemicals industries produces generic aids and malaria drugs. its able to export it to neighbouring countries and even to south africa. it has gone a long way to build capacity in the fight against hiv/aids and malaria

16:29:57
From Lynette Mabote to Everyone: Amazing presentation Eduardo. Thank you. I did my LLM on CLs mechanisms (IPR framework) comparing SA, Russia and China. I found that we also need to consider models/ mechanisms for securing CLs, as these also present barriers. Did you find this in your research?

16:30:20
From Global Health Centre Research, Graduate Institute Geneva to Everyone: The research paper being presented by Dr Danielle Navarro is available at: https://www.knowledgeportalia.org/compulsory-licensing

16:39:47
From Lynette Mabote to Everyone: Thank you for the great presentation Danielle. Did you find that countries opted to use Competition Law in lieu of CLs and the impact this, given the complexities of legal systems in applying for CLs in some countries?

16:40:46
From Suerie Moon to Everyone: Thank you both for the excellent presentations! A question for Profs Urias and Ramani. Could industrial policy also be health policy -- that is, can a CL serve both simultaneously?

16:42:06
From Enrica Alteri to Everyone: Does CL imply regulatory approval? If not, what is the experience in the countries that used it?

16:42:14
From Philbert Nshimiyimana to Everyone: Thank you for interesting presentation. I believe that compulsory licensing should be encouraged especially during the times of PHEs like this of current COVID-19 where the life-saving products needed cannot be produced by one, two or few countries....However, in normal condition, it should be given much attention.

16:43:20
From Enrica Alteri to Everyone: Thanks Eduardo!

16:45:01
From Yuanqiong Hu to Panelists: Thanks for the presentation. I would also like to share a recent briefing paper we published on CL and the limitations in the pandemic, for your reference:
https://msfaccess.org/sites/default/files/2021-05/COVID_TechBrief_MSF_AC_IP_CompulsoryLicensesTRIPSWaiver_ENG_21May2021_0.pdf

16:45:35
From Eduardo Urias to Everyone: thank you, yuanqiong!

16:45:53
From Suerie Moon to Everyone: Perhaps one reason CLs have been used by some LMICs is bc any govt can use this tool, one does not need a large market to use as negotiating leverage as with price negotiation or price regulation. With that in mind what other policy tools might LMIC govts use to complement CLs, with the understanding they are useful but cannot solve every problem?

16:48:01
From Rosa Jahn to Everyone: Thanks a lot to both presenters for these great presentations. I was wondering what you think about CL and the TRIPS waiver that has been proposed in the WTO. Which approach do you think would be more likely or more useful to improve access to the covid-19 vaccines? Should the global health community focus on promoting the use of CL for Covid, at the risk of taking away momentum from the push for the waiver; or would the waiver be the more promising approach?

16:58:30
From Magalie Schotte to Everyone: What do you think about the statement of Michelle Bachelet, United Nations High Commissioner for Human Rights that Vaccines against COVID-19 Must Be Considered as a Global Public Good?

16:58:47
From Susan Adong to Everyone: india granted that to Uganda

16:59:41
From Suerie Moon to Everyone: @Yuanqiong, would you mind reposting to All panelists and attendees? It didn't show up, at least on my feed

17:00:23
From Elpidio Peria to Panelists: reaction to Ramani's point on countries foregoing technological capacity devt, but isn't Cuba able to develop its own vaccine, or even that takes a long-term effort?

17:00:48
From Global Health Centre Research, Graduate Institute Geneva to Everyone: https://www.knowledgeportalia.org/covid-19-resources

17:01:07
From Yuanqiong Hu to Everyone: @Surie, thanks, I will try here again here :) @Rosa, we did a quick scenario comparison in the technical briefing I shared above reg. CL and the TRIPS waiver, concluding that CL is not adapted to the pandemic context and additional rules are needed. But that represents our analysis and position, and happy to hear how the others think:
https://msfaccess.org/sites/default/files/2021-05/COVID_TechBrief_MSF_AC_IP_CompulsoryLicensesTRIPSWaiver_ENG_21May2021_0.pdf.

17:01:32
From Suerie Moon to Everyone: Thank you for this very intriguing discussion and presentations, very useful!

17:02:17
From Alice Dartevelle to Everyone: Thank you very much for the excellent work you have done with regards to covid-19 on the knowledge portal, those are very valuable information ! Thank you !!

17:02:39
From Eduardo Urias to Everyone: Thank you all!

17:02:46
From Rosa Jahn to Everyone: @Yuanqiong thanks a lot, that's great!

17:02:48
From Yesenia Rodríguez to Panelists: thank u!

17:02:54
From Yuanqiong Hu to Everyone: Thanks for the session. One quick last comment is that the TRIPS waiver covers also therapeutics, diagnostics and raw materials, there are much more capacities in LMICs to produce those products that are equally needed .